Current Neurology and Neuroscience Reports

, Volume 8, Issue 2, pp 114–122 | Cite as

Neurotoxicity of chemotherapeutic and biologic agents in children with cancer



The sequelae of treatment modalities used to treat childhood cancer are of increasing clinical importance. In children with pediatric malignancies, the full impact of such sequelae may not be apparent until years after treatment. The earlier recognition of these neurotoxicities could possibly alter the course of a treatment or facilitate interventions to improve quality of life.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    National Cancer Institute: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at Accessed November 1, 2007.
  2. 2.
    Casciato DA (editor): Manual of Clinical Oncology, edn 5. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
  3. 3.
    Ettinger LJ, Freeman AI, Creaven PJ: Intrathecal methotrexate overdose without neurotoxicity: case report and literature review. Cancer 1978, 41:1270–1273.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruggiero A, Ruggiero A, Conter V, Milani M: Intrathecal chemotherapy with antineoplastic agents in children. Pediatr Drugs 2001, 3:237–246.CrossRefGoogle Scholar
  5. 5.
    Haykin ME, Gorman M, van Hoff J, et al.: Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity. J Neurooncol 2006, 76:153–157.Google Scholar
  6. 6.
    Dufourg MN, Landman-Parker J, Auclerc MF, et al.: Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 2007, 21:238–247.PubMedCrossRefGoogle Scholar
  7. 7.
    Mahoney DH Jr, Shuster JJ, Nitschke R, et al.: Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy—a Pediatric Oncology Group study. J Clin Oncol 1998, 16:1712–1722.PubMedGoogle Scholar
  8. 8.
    Lo Nigro L, Di Cataldo A, Schiliro G: Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 2000, 35:449–455.PubMedCrossRefGoogle Scholar
  9. 9.
    Winick NJ, Bowman WP, Kamen BA, et al.: Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992, 84:252–256.PubMedCrossRefGoogle Scholar
  10. 10.
    Riva D, Giorgi C, Nichelli F, et al.: Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 2002, 9:59:48–53.Google Scholar
  11. 11.
    Rutkowski S, Bode U, Deinlein F, et al.: Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005, 352:978–986.PubMedCrossRefGoogle Scholar
  12. 12.
    Koh S, Nelson MD Jr, Kovanlikaya A, et al.: Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999, 21:576–578.PubMedCrossRefGoogle Scholar
  13. 13.
    van den Berg H, van der Flier M, van de Wetering MD: Cytarabine-induced aseptic meningitis. Leukemia 2001, 15:697–699.PubMedCrossRefGoogle Scholar
  14. 14.
    Benesch M, Sovinz P, Krammer B, et al.: Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007, 29:222–226.PubMedCrossRefGoogle Scholar
  15. 15.
    Posner JB: Contemporary Neurology Series: Neurologic Complications of Cancer, Vol. 45. New York: Oxford University Press; 1995.Google Scholar
  16. 16.
    Hovi L, Era P, Rautonen J, et al.: Impaired muscle strength in female adolescents and young adults surviving leukemia in childhood. Cancer 1993, 72:276–281.PubMedCrossRefGoogle Scholar
  17. 17.
    Kieslich M, Porto L, Lanfermann H, et al.: Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003, 25:484–487.PubMedCrossRefGoogle Scholar
  18. 18.
    Aytac S, Yetgin S, Tavil B: Acute and long-term neurologic complications in children with acute lymphoblastic leukemia. Turk J Pediatr 2006, 48:1–7.PubMedGoogle Scholar
  19. 19.
    Trinkle R, Wu JK: Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol 1996, 26:344–351.PubMedCrossRefGoogle Scholar
  20. 20.
    Tabori U, Sung L, Hukin J, et al.: Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer 2005, 103:1874–1880.PubMedCrossRefGoogle Scholar
  21. 21.
    Riga M, Korres S, Psarommatis I, et al.: Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1–f2 distortion product otoacoustic emissions. Otol Neurotol 2007, 28:208–212.PubMedCrossRefGoogle Scholar
  22. 22.
    Schiavetti A, Frascarelli M, Uccini S, Novelli A: Vincristine neuropathy: neurophysiological and genetic studies in a case of Wilms tumor. Pediatr Blood Cancer 2004, 43:606–609.PubMedCrossRefGoogle Scholar
  23. 23.
    Bermudez M, Fuster JL, Llinares E, et al.: Itraconazolerelated increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol 2005, 27:389–392.PubMedCrossRefGoogle Scholar
  24. 24.
    Bertolini P, Lassalle M, Mercier G, et al.: Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004, 26:649–655.PubMedCrossRefGoogle Scholar
  25. 25.
    Brock PR, Bellman SC, Yeomans EC, et al.: Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991, 19:295–300.PubMedCrossRefGoogle Scholar
  26. 26.
    Gilmer Knight KR, Kraemer DF, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: underestimating acommonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005, 23:8588–8596.CrossRefGoogle Scholar
  27. 27.
    Sastry J, Kellie SJ: Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 2005, 22:441–445.PubMedCrossRefGoogle Scholar
  28. 28.
    Watterson J, Toogood I, Nieder M, et al.: Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994, 74:3034–3041.PubMedCrossRefGoogle Scholar
  29. 29.
    Razzouk BI, Heideman RL, Friedman HS, et al.: A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 1995, 75:2762–2767.PubMedCrossRefGoogle Scholar
  30. 30.
    Ridola V, Grill J, Doz F, et al.: High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy. Cancer 2007, 110:156–163.PubMedCrossRefGoogle Scholar
  31. 31.
    Valteau-Couanet D, Fillipini B, Benhamou E, et al.: High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy. Bone Marrow Transplant 2005, 36:939–945.PubMedCrossRefGoogle Scholar
  32. 32.
    Fagioli F, Biasin E, Mastrodicasa L, et al.: High-dose thiotepa and etoposide in children with poor-prognosis brain tumors. Cancer 2004, 100:2215–2221.PubMedCrossRefGoogle Scholar
  33. 33.
    Modak S, Gardner S, Dunkel IJ, et al.: Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol 2004, 22:1934–1943.PubMedCrossRefGoogle Scholar
  34. 34.
    Blaney SM, Heideman R, Berg S, et al.: Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003, 21:143–147.PubMedCrossRefGoogle Scholar
  35. 35.
    Bomgaars LR, Bernstein M, Krailo M, et al.: Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 2007, 25:4622–4627.PubMedCrossRefGoogle Scholar
  36. 36.
    Vassal G, Couanet D, Stockdale E, et al.: Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children’s Cancer Study Group. J Clin Oncol 2007, 25:356–361.PubMedCrossRefGoogle Scholar
  37. 37.
    Pappo AS, Lyden E, Breitfeld P, et al.: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children’s Oncology Group. J Clin Oncol 2007, 25:362–369.PubMedCrossRefGoogle Scholar
  38. 38.
    Bisogno G, Riccardi R, Ruggiero A, et al.: Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 2006, 106:703–707.PubMedCrossRefGoogle Scholar
  39. 39.
    Gentet JC, Patte C, Quintana E, et al.: Phase II study of cytarabine and etoposide in children with refractory or relapsed non-Hodgkin’s lymphoma: a study of the French Society of Pediatric Oncology. J Clin Oncol 1990, 8:661–665.PubMedGoogle Scholar
  40. 40.
    Simon T, Langler A, Berthold F, et al.: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol 2007, 29:101–106.PubMedCrossRefGoogle Scholar
  41. 41.
    McTiernan A, Meyer T, Michelagnoli MP, et al.: A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. Pediatr Blood Cancer 2006, 46:345–350.PubMedCrossRefGoogle Scholar
  42. 42.
    Van Winkle P, Angiolillo A, Krailo M, et al.: Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children’s Cancer Group (CCG) experience. Pediatr Blood Cancer 2005, 44:338–347.PubMedCrossRefGoogle Scholar
  43. 43.
    Blaney SM, Balis FM, Berg S, et al.: Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005, 23:1555–1563.PubMedCrossRefGoogle Scholar
  44. 44.
    Slavc I, Schuller E, Czech T, et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998, 38:213–218.PubMedCrossRefGoogle Scholar
  45. 45.
    Slavc I, Schuller E, Falger J, et al.: Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003, 64:239–247.PubMedCrossRefGoogle Scholar
  46. 46.
    Nicolao P, Giometto B: Neurological toxicity of ifosfamide. Oncology 2003, 65(Suppl 2):11–16.PubMedCrossRefGoogle Scholar
  47. 47.
    Pratt CB, Green AA, Horowitz ME, et al.: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986, 4:1253–1261.PubMedGoogle Scholar
  48. 48.
    Pelgrims J, De Vos F, Van den Brande J, et al.: Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000, 82:291–294.PubMedCrossRefGoogle Scholar
  49. 49.
    Arceci RJ, Sande J, Lange B, et al.: Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005, 106:1183–1188.PubMedCrossRefGoogle Scholar
  50. 50.
    Giulino LB, Bussel JB, Neufeld EJ: Treatment with rituximab in benign and malignant hematologic disorders in children.; Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. J Pediatr 2007, 150:338–344.PubMedCrossRefGoogle Scholar
  51. 51.
    Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153–2164.PubMedGoogle Scholar
  52. 52.
    Petropoulos D, Worth LL, Mullen CA, et al.: Interferonalpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin’s lymphoma. Bone Marrow Transplant 2006, 38:345–349.PubMedCrossRefGoogle Scholar
  53. 53.
    Wilson MW, Hoehn ME, Haik BG, et al.: Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 2007, 114:1007–1011.PubMedCrossRefGoogle Scholar
  54. 54.
    Ezekowitz RA, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992, 326:1456–1463.PubMedCrossRefGoogle Scholar
  55. 55.
    Wolff JE, Wagner S, Reinert C, et al.: Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol 2006, 79:315–321.PubMedCrossRefGoogle Scholar
  56. 56.
    Kishi S, Cheng C, French D, et al.: Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007, 109:4151–4157.PubMedCrossRefGoogle Scholar
  57. 57.
    Cheok MH, Evans WE: Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006, 6:117–129. Erratum in Nat Rev Cancer 2006, 6:249.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Division of NeurologyChildren’s National Medical CenterWashington, DCUSA

Personalised recommendations